Evoniks, Standalone

Evonik's Standalone Case Gets a 19-Euro Yardstick as Oddo Steps Back From Outperform

Published on 11/21/2026 at 15:43 | Editorial boerse-global.de
Oddo BHF downgraded Evonik to Neutral and cut its price target to €19, days after BASF ended takeover talks. Evonik closed at €18.18.
Evoniks, Standalone, Case, Gets, Yardstick, Oddo, Steps, Back, From, Outperform Illustration mit AI erstellt.

Oddo BHF has cut its rating on Evonik from "Outperform" to "Neutral" and trimmed its price target from 22 to 19 euros, according to media reports from yesterday. The new objective sits barely above Friday's close of €18.18 — leaving investors with little cushion to price in any meaningful rebound.

The downgrade lands just days after BASF walked away from its pursuit of the specialty chemicals group. Reuters reported that BASF ended its takeover efforts on Thursday, having seen Evonik reject two non-binding all-cash offers. The most recent bid valued Evonik at €24 per share, or roughly €11.2 billion for the company. That figure, however, is not a valuation floor: it belonged to an offer Evonik turned down, and any standalone assessment must rest on the earnings Evonik can generate on its own.

What It Would Take to Reopen Talks

Bernstein analyst James Hooper sees a path back to the negotiating table — but a narrow one. In his view, Evonik would have to approach BASF and demonstrate a value above €24 per share. That is a description of the hurdles, not a forecast of a fresh bid.

The logic cuts both ways. Evonik is betting on its own growth strategy, while BASF judged that a higher price was not justified given the risks facing Evonik's standalone prospects. BASF also cited its failure to secure access to a deeper due diligence review as a reason for pulling back this week. Interim CEO Claus Rettig has made clear he intends to press ahead with the independent growth plan.

Should investors sell immediately? Or is it worth buying Evonik?

Hooper's scenario therefore hinges on more than price alone. Evonik would first need to be willing to engage, then convince BASF that the business is worth more than the last offer implied. After Thursday's share-price slide, the stock closed yesterday at €18.18 — below the most recent bid. That gap represents no arbitrage opportunity while no new offer is on the table.

A Major Holder's Regret, Not an Endorsement

RAG-Stiftung, Evonik's largest shareholder, said yesterday it regretted that in-depth talks between the two boards never materialized. That expression of disappointment should not be read as support for a sale on the terms offered. The foundation intends to reduce its stake step by step to 25.1% and to expand other capital investments in order to fund the follow-on costs of hard-coal mining — a stated ownership target, not a completed sale. Additional selling pressure would be a risk only if further share disposals follow, not a consequence of the confirmation itself.

Politics, too, played a part. The Frankfurter Allgemeine Zeitung reported that political resistance was a decisive factor in BASF's retreat. North Rhine-Westphalia's state premier, Hendrik Wüst, pointed to 11,000 Evonik jobs in the region, according to the paper. BASF had already offered protections for sites, research and employment in Germany through 2032 back in October.

Earnings, Not the Old Bid, Are the Real Test

For shareholders, the standalone story only gains weight if it translates into stronger earnings power. Should profitability improve, the stock could command a higher valuation without any new offer — and the earlier bid price would be neither a prerequisite nor a target. Rettig told Reuters on Thursday that the withdrawal removes a source of uncertainty for employees and lets Evonik focus on developing independently.

The flip side is less comforting. If operating results come in weaker than expected, even the lowered price target offers no safety net, and the assumption that the recent decline already discounts enough risk would come under strain. Until better earnings show up in the numbers, the old €24 bid provides no solid basis for a recovery. The next published set of business figures is the real proving ground.

Ad

Evonik Stock: New Analysis - 21 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIKS | boerse | 70542817 |